EA202192183A1 - Композиции, обладающие активностью удаления липофусцина из клеток сетчатки - Google Patents

Композиции, обладающие активностью удаления липофусцина из клеток сетчатки

Info

Publication number
EA202192183A1
EA202192183A1 EA202192183A EA202192183A EA202192183A1 EA 202192183 A1 EA202192183 A1 EA 202192183A1 EA 202192183 A EA202192183 A EA 202192183A EA 202192183 A EA202192183 A EA 202192183A EA 202192183 A1 EA202192183 A1 EA 202192183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lipofuscin
compositions
removal activity
retina cells
diseases
Prior art date
Application number
EA202192183A
Other languages
English (en)
Inventor
Марсело М. Нучари
Энрике Родригес Боулан
Original Assignee
Корнелл Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Корнелл Юниверсити filed Critical Корнелл Юниверсити
Publication of EA202192183A1 publication Critical patent/EA202192183A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение в целом относится к композициям и способам лечения заболеваний глаз (например, ретинопатий) и, в частности, к лечению заболеваний глаз, связанных с накоплением липофусцина в клетках сетчатки.
EA202192183A 2019-03-05 2020-03-03 Композиции, обладающие активностью удаления липофусцина из клеток сетчатки EA202192183A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814028P 2019-03-05 2019-03-05
PCT/US2020/020805 WO2020180872A1 (en) 2019-03-05 2020-03-03 Compositions of matter with activity to remove lipofuscin from retinal cells

Publications (1)

Publication Number Publication Date
EA202192183A1 true EA202192183A1 (ru) 2022-01-14

Family

ID=72337111

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192183A EA202192183A1 (ru) 2019-03-05 2020-03-03 Композиции, обладающие активностью удаления липофусцина из клеток сетчатки

Country Status (14)

Country Link
US (1) US20220118002A1 (ru)
EP (1) EP3934660A4 (ru)
JP (1) JP2022525007A (ru)
KR (1) KR20210142651A (ru)
CN (1) CN113747902A (ru)
AU (1) AU2020232266A1 (ru)
BR (1) BR112021017529A2 (ru)
CA (1) CA3132466A1 (ru)
CO (1) CO2021012267A2 (ru)
EA (1) EA202192183A1 (ru)
IL (1) IL286002A (ru)
MX (1) MX2021010650A (ru)
SG (1) SG11202109541YA (ru)
WO (1) WO2020180872A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
WO2014152959A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2016168772A1 (en) * 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
GB2556082A (en) * 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition

Also Published As

Publication number Publication date
WO2020180872A1 (en) 2020-09-10
US20220118002A1 (en) 2022-04-21
BR112021017529A2 (pt) 2021-11-09
AU2020232266A1 (en) 2021-09-23
CN113747902A (zh) 2021-12-03
MX2021010650A (es) 2021-12-10
CA3132466A1 (en) 2020-09-10
CO2021012267A2 (es) 2021-10-20
IL286002A (en) 2021-10-31
EP3934660A1 (en) 2022-01-12
EP3934660A4 (en) 2022-11-23
SG11202109541YA (en) 2021-09-29
JP2022525007A (ja) 2022-05-11
KR20210142651A (ko) 2021-11-25

Similar Documents

Publication Publication Date Title
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
IL282624A (en) Methods and compositions for the treatment of sight beard, mydriasis and other disorders of the eyes
JOP20170147B1 (ar) تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
BR112014008759A2 (pt) tratamento de doença ocular
MX2020001644A (es) Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes.
EA202092779A1 (ru) Замещенные дигидропиразолопиразинкарбоксамидные производные
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX2020000713A (es) Metodos de aferesis y sus usos.
CO2019012336A2 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
EA202090966A1 (ru) МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.